デフォルト表紙
市場調査レポート
商品コード
1760559

ハンチントン病治療の世界市場レポート 2025年

Huntington's Disease Treatment Global Market Report 2025


出版日
ページ情報
英文 175 Pages
納期
2~10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.89円
ハンチントン病治療の世界市場レポート 2025年
出版日: 2025年07月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2~10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

ハンチントン病治療市場規模は、今後数年で急成長が見込まれます。2029年には13億5,000万米ドルに成長し、CAGRは13.0%となります。この予測期間における成長は、個別化医療への注目の高まり、デジタルヘルスモニタリングの統合の進展、希少疾病用医薬品に対する規制当局の支援の強化、対症療法を提供する治療に対する需要の高まり、疾患修飾性治療に対する需要の高まりによって牽引されると予測されます。この期間の主な動向としては、技術主導の遺伝子サイレンシングツールの発展、細胞ベースの治療法の開発、末梢バイオマーカーの出現、ハンチントン病治療への遠隔医療の統合、患者報告アウトカムの取り込み、疾患修飾薬の継続的な技術革新などが考えられます。

ハンチントン病治療市場の成長を牽引するのは、遺伝的原因を標的とし、疾患の進行を遅らせる遺伝子治療の利用拡大であると予想されます。遺伝子治療とは、遺伝子レベルで病気を治したり予防したりするために、欠陥のある遺伝子を変えたり置き換えたりする治療法です。精密医療が進歩し続ける中、遺伝子治療は根本的な遺伝的原因を直接標的とする能力を提供し、従来の治療と比較して治療成績の改善につながります。ハンチントン病では、遺伝子治療は有害なタンパク質を産生する欠陥のあるHTT遺伝子を沈黙させ、神経細胞の損傷を防ぐことを目的としています。このアプローチは、病気の進行を遅らせ、脳機能を保護し、長期的なコントロールの可能性をもたらします。例えば、2023年7月、米国遺伝子・細胞治療学会(ASGCT)とCiteline社は、第2相臨床試験中の遺伝子治療薬の数が、2023年第2四半期末までに247から260に5%増加したと報告しました。このように、遺伝子治療の増加が市場の成長に寄与しています。

ハンチントン病治療市場の各社は、選択的小胞モノアミントランスポーター2(VMAT2)阻害剤カプセルのような、患者のQOLを向上させながら疾患の進行を遅らせることを目的とした開発にも注力しています。VMAT2阻害剤は、脳内で放出される神経伝達物質のパッケージングに関与するタンパク質を阻害することによって作用します。これらの薬剤は神経伝達物質の放出を抑え、不随意運動やその他の関連症状の管理に役立ちます。例えば、ニューロクライン・バイオサイエンス社は2023年8月、成人のハンチントン病に伴う舞踏病の治療薬として、1日1回経口投与のVMAT2阻害剤であるIngrezza(バルベナジン)カプセルのFDA承認を取得しました。本剤は、脳内の過剰なドーパミンシグナル伝達を抑制することにより不随意運動を抑制する薬剤であり、様々な強さのカプセルが用意されているため、患者にとって利便性の高い投与方法を選択することができます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界ハンチントン病治療PESTEL分析(政治、社会、技術、環境、法的要因、促進要因と抑制要因)
  • 最終用途産業の分析
  • 世界のハンチントン病治療市場:成長率分析
  • 世界のハンチントン病治療市場の実績:規模と成長、2019~2024年
  • 世界のハンチントン病治療市場の予測:規模と成長、2024~2029年、2034年
  • 世界ハンチントン病治療総アドレス可能市場(TAM)

第6章 市場セグメンテーション

  • 世界のハンチントン病治療市場:処置別、実績と予測、2019~2024年、2024~2029年、2034年
  • 治療
  • 疾患修飾療法
  • 世界のハンチントン病治療市場:投与タイプ別、実績と予測、2019~2024年、2024~2029年、2034年
  • オーラル
  • 静脈内
  • 皮下
  • 局所
  • 世界のハンチントン病治療市場:治療別、実績と予測、2019~2024年、2024~2029年、2034年
  • 遺伝性疾患
  • 神経疾患
  • 精神疾患
  • 世界のハンチントン病治療市場:流通チャネル別、実績と予測、2019~2024年、2024~2029年、2034年
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界のハンチントン病治療市場:エンドユーザー別、実績と予測、2019~2024年、2024~2029年、2034年
  • 病院
  • クリニック
  • 在宅ケア設定
  • 研究センター
  • 世界のハンチントン病治療市場:対処療法、種類別、実績と予測、2019~2024年、2024~2029年、2034年
  • 抗うつ薬
  • 抗精神病薬
  • 気分安定剤
  • 舞踏病治療薬
  • 認知機能向上剤
  • 世界のハンチントン病治療市場:疾患修飾療法の種類別、実績と予測、2019~2024年、2024~2029年、2034年
  • 遺伝子治療
  • 神経保護剤
  • RNAベースの治療法
  • 幹細胞療法
  • タンパク質標的療法

第7章 地域別・国別分析

  • 世界のハンチントン病治療市場:地域別、実績と予測、2019~2024年、2024~2029年、2034年
  • 世界のハンチントン病治療市場:国別、実績と予測、2019~2024年、2024~2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • ハンチントン病治療市場:競合情勢
  • ハンチントン病治療市場:企業プロファイル
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Vertex Pharmaceuticals Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Sun Pharmaceutical Industries Inc.
  • H. Lundbeck A/S
  • WaVe Life Sciences Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Hikma Pharmaceuticals plc
  • Lupin Limited
  • Neurocrine Biosciences Inc.
  • Alnylam Pharmaceuticals Inc.
  • PTC Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • Annexon Inc.
  • Uniqure NV
  • Sage Therapeutics Inc.
  • Azevan Pharmaceuticals Inc.
  • Prilenia Therapeutics B.V.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • ハンチントン病治療市場、2029年:新たな機会を提供する国
  • ハンチントン病治療市場、2029年:新たな機会を提供するセグメント
  • ハンチントン病治療市場、2029年:成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r35436

Huntington's disease treatment consists of medical therapies aimed at managing the symptoms of this progressive neurological condition. The main objective is to slow the disease's progression, reduce symptoms, and improve the patient's quality of life.

The primary types of treatment for Huntington's disease are symptomatic treatments and disease-modifying therapies. Symptomatic treatments focus on alleviating the symptoms of Huntington's disease and enhancing quality of life, without targeting the underlying cause. These treatments are becoming increasingly sought after as patients look for better ways to manage daily challenges. Various methods are used to administer these treatments, including oral, intravenous, subcutaneous, and topical routes, for applications in genetic, neurological, and psychiatric disorders. These treatments are available through multiple distribution channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of end users, including hospitals, clinics, home care settings, and research institutions.

The Huntington's disease treatment market research report is one of a series of new reports from The Business Research Company that provides Huntington's disease treatment market statistics, including the Huntington's disease treatment industry's global market size, regional shares, competitors with the Huntington's disease treatment market share, detailed Huntington's disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Huntington's disease treatment market. This Huntington's disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The Huntington's disease treatment market size has grown rapidly in recent years. It will grow from $0.73 billion in 2024 to $0.83 billion in 2025 at a compound annual growth rate (CAGR) of 13.3%. The growth observed in the historical period can be attributed to several factors, including increased awareness of genetic disorders, improved accessibility to genetic testing, higher investment in neurodegenerative disease research, a rise in the number of clinical trials for experimental therapies, and a growing pipeline of disease-modifying drugs.

The Huntington's disease treatment market size is expected to see rapid growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 13.0%. The growth in the forecast period is expected to be driven by a stronger focus on personalized medicine, greater integration of digital health monitoring, increased regulatory support for orphan drugs, rising demand for therapies that provide symptomatic relief, and a higher demand for disease-modifying treatments. Key trends during this period are likely to include advancements in technology-driven gene silencing tools, the development of cell-based therapies, the emergence of peripheral biomarkers, the integration of telehealth into Huntington's disease care, the incorporation of patient-reported outcomes, and continued innovation in disease-modifying drugs.

The growth of the Huntington's disease treatment market is expected to be driven by the increasing use of gene therapies, which target genetic causes and slow disease progression. Gene therapies are treatments that alter or replace defective genes to cure or prevent diseases at the genetic level. As precision medicine continues to advance, gene therapies offer the ability to directly target the underlying genetic causes, leading to improved outcomes compared to traditional treatments. In Huntington's disease, gene therapies aim to silence the defective HTT gene that produces harmful proteins, thus preventing nerve cell damage. This approach helps slow disease progression, protect brain function, and provides potential for long-term control. For example, in July 2023, the American Society of Gene & Cell Therapy (ASGCT) and Citeline reported that the number of gene therapies in phase II clinical trials increased by 5% from 247 to 260 by the end of Q2 2023. As such, the increase in gene therapies is contributing to the market's growth.

Companies in the Huntington's disease treatment market are also focusing on the development of advanced therapies, such as selective vesicular monoamine transporter 2 (VMAT2) inhibitor capsules, which aim to improve patient quality of life while slowing disease progression. VMAT2 inhibitors work by blocking a protein involved in packaging neurotransmitters for release in the brain. These drugs reduce neurotransmitter release, helping manage involuntary movements and other related symptoms. For example, in August 2023, Neurocrine Biosciences received FDA approval for Ingrezza (valbenazine) capsules, a once-daily oral VMAT2 inhibitor for the treatment of chorea associated with Huntington's disease in adults. This medication helps control involuntary movements by reducing excessive dopamine signaling in the brain and is available in various strengths, offering a convenient dosing option for patients.

In December 2024, PTC Therapeutics, a US-based pharmaceutical company developing treatments for Huntington's disease, entered into a partnership with Novartis AG to advance the development of PTC518, a potential first-in-class oral, disease-modifying therapy for Huntington's disease. This collaboration aims to accelerate the development and global commercialization of PTC518. Novartis AG, a Switzerland-based pharmaceutical company, specializes in drugs for Huntington's disease.

Major players in the huntington's disease treatment market are F. Hoffmann-La Roche Ltd., Novartis AG, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Bausch Health Companies Inc., Sun Pharmaceutical Industries Inc., H. Lundbeck A/S, WaVe Life Sciences Ltd., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Lupin Limited, Neurocrine Biosciences Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Annexon Inc., Uniqure NV, Sage Therapeutics Inc., Azevan Pharmaceuticals Inc., Prilenia Therapeutics B.V.

North America was the largest region in the Huntington's disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in Huntington's disease treatment report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the Huntington's disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The Huntington's disease treatment market consists of sales of products including tetrabenazine, deutetrabenazine, huntingtin-lowering therapies, cannabinoids, and cognitive enhancers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Huntington's Disease Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on huntington's disease treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for huntington's disease treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The huntington's disease treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Symptomatic Treatment; Disease-Modifying Therapies
  • 2) By Administration Type: Oral; Intravenous; Subcutaneous; Topical
  • 3) By Therapeutic: Genetic Disorders; Neurological Disorders; Psychiatric Disorders
  • 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 5) By End-User: Hospitals; Clinics; Homecare Settings; Research Centers

Subsegments

  • 1) By Symptomatic Treatment: Antidepressants; Antipsychotics; Mood Stabilizers; Chorea Medications; Cognitive Enhancers
  • 2) By Disease-Modifying Therapies: Gene Therapy; Neuroprotective Agents; RNA-Based Therapies; Stem Cell Therapy; Protein-Targeting Therapies
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Vertex Pharmaceuticals Incorporated; Bausch Health Companies Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Huntington's Disease Treatment Market Characteristics

3. Huntington's Disease Treatment Market Trends And Strategies

4. Huntington's Disease Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Huntington's Disease Treatment Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Huntington's Disease Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Huntington's Disease Treatment Market Growth Rate Analysis
  • 5.4. Global Huntington's Disease Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Huntington's Disease Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Huntington's Disease Treatment Total Addressable Market (TAM)

6. Huntington's Disease Treatment Market Segmentation

  • 6.1. Global Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Symptomatic Treatment
  • Disease-Modifying Therapies
  • 6.2. Global Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Oral
  • Intravenous
  • Subcutaneous
  • Topical
  • 6.3. Global Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genetic Disorders
  • Neurological Disorders
  • Psychiatric Disorders
  • 6.4. Global Huntington's Disease Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.5. Global Huntington's Disease Treatment Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Clinics
  • Homecare Settings
  • Research Centers
  • 6.6. Global Huntington's Disease Treatment Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antidepressants
  • Antipsychotics
  • Mood Stabilizers
  • Chorea Medications
  • Cognitive Enhancers
  • 6.7. Global Huntington's Disease Treatment Market, Sub-Segmentation Of Disease-Modifying Therapies, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gene Therapy
  • Neuroprotective Agents
  • RNA-Based Therapies
  • Stem Cell Therapy
  • Protein-Targeting Therapies

7. Huntington's Disease Treatment Market Regional And Country Analysis

  • 7.1. Global Huntington's Disease Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Huntington's Disease Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Huntington's Disease Treatment Market

  • 8.1. Asia-Pacific Huntington's Disease Treatment Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Huntington's Disease Treatment Market

  • 9.1. China Huntington's Disease Treatment Market Overview
  • 9.2. China Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Huntington's Disease Treatment Market

  • 10.1. India Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Huntington's Disease Treatment Market

  • 11.1. Japan Huntington's Disease Treatment Market Overview
  • 11.2. Japan Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Huntington's Disease Treatment Market

  • 12.1. Australia Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Huntington's Disease Treatment Market

  • 13.1. Indonesia Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Huntington's Disease Treatment Market

  • 14.1. South Korea Huntington's Disease Treatment Market Overview
  • 14.2. South Korea Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Huntington's Disease Treatment Market

  • 15.1. Western Europe Huntington's Disease Treatment Market Overview
  • 15.2. Western Europe Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Huntington's Disease Treatment Market

  • 16.1. UK Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Huntington's Disease Treatment Market

  • 17.1. Germany Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Huntington's Disease Treatment Market

  • 18.1. France Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Huntington's Disease Treatment Market

  • 19.1. Italy Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Huntington's Disease Treatment Market

  • 20.1. Spain Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Huntington's Disease Treatment Market

  • 21.1. Eastern Europe Huntington's Disease Treatment Market Overview
  • 21.2. Eastern Europe Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Huntington's Disease Treatment Market

  • 22.1. Russia Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Huntington's Disease Treatment Market

  • 23.1. North America Huntington's Disease Treatment Market Overview
  • 23.2. North America Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Huntington's Disease Treatment Market

  • 24.1. USA Huntington's Disease Treatment Market Overview
  • 24.2. USA Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Huntington's Disease Treatment Market

  • 25.1. Canada Huntington's Disease Treatment Market Overview
  • 25.2. Canada Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Huntington's Disease Treatment Market

  • 26.1. South America Huntington's Disease Treatment Market Overview
  • 26.2. South America Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Huntington's Disease Treatment Market

  • 27.1. Brazil Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Huntington's Disease Treatment Market

  • 28.1. Middle East Huntington's Disease Treatment Market Overview
  • 28.2. Middle East Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Huntington's Disease Treatment Market

  • 29.1. Africa Huntington's Disease Treatment Market Overview
  • 29.2. Africa Huntington's Disease Treatment Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Huntington's Disease Treatment Market, Segmentation By Administration Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Huntington's Disease Treatment Market, Segmentation By Therapeutic, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Huntington's Disease Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Huntington's Disease Treatment Market Competitive Landscape
  • 30.2. Huntington's Disease Treatment Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Teva Pharmaceutical Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Vertex Pharmaceuticals Incorporated Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Bausch Health Companies Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Huntington's Disease Treatment Market Other Major And Innovative Companies

  • 31.1. Sun Pharmaceutical Industries Inc.
  • 31.2. H. Lundbeck A/S
  • 31.3. WaVe Life Sciences Ltd.
  • 31.4. Dr. Reddy's Laboratories Ltd.
  • 31.5. Hikma Pharmaceuticals plc
  • 31.6. Lupin Limited
  • 31.7. Neurocrine Biosciences Inc.
  • 31.8. Alnylam Pharmaceuticals Inc.
  • 31.9. PTC Therapeutics Inc.
  • 31.10. Ionis Pharmaceuticals Inc.
  • 31.11. Annexon Inc.
  • 31.12. Uniqure NV
  • 31.13. Sage Therapeutics Inc.
  • 31.14. Azevan Pharmaceuticals Inc.
  • 31.15. Prilenia Therapeutics B.V.

32. Global Huntington's Disease Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Huntington's Disease Treatment Market

34. Recent Developments In The Huntington's Disease Treatment Market

35. Huntington's Disease Treatment Market High Potential Countries, Segments and Strategies

  • 35.1 Huntington's Disease Treatment Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Huntington's Disease Treatment Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Huntington's Disease Treatment Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer